Illumina, Inc. $ILMN Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 63,895 shares of the life sciences company’s stock, valued at approximately $17,487,000.

Several other hedge funds also recently made changes to their positions in ILMN. ProShare Advisors LLC raised its holdings in Illumina by 165.8% in the 3rd quarter. ProShare Advisors LLC now owns 30,204 shares of the life sciences company’s stock valued at $8,266,000 after acquiring an additional 18,841 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in shares of Illumina by 8.7% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 1,394 shares of the life sciences company’s stock worth $382,000 after purchasing an additional 111 shares in the last quarter. MGO One Seven LLC grew its holdings in shares of Illumina by 4.3% during the 3rd quarter. MGO One Seven LLC now owns 5,310 shares of the life sciences company’s stock worth $1,453,000 after purchasing an additional 217 shares in the last quarter. International Assets Investment Management LLC grew its holdings in shares of Illumina by 10,608.7% during the 3rd quarter. International Assets Investment Management LLC now owns 55,257 shares of the life sciences company’s stock worth $15,123,000 after purchasing an additional 54,741 shares in the last quarter. Finally, Soltis Investment Advisors LLC increased its position in shares of Illumina by 29.6% in the third quarter. Soltis Investment Advisors LLC now owns 1,994 shares of the life sciences company’s stock worth $546,000 after purchasing an additional 455 shares during the period. 89.42% of the stock is owned by institutional investors.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT study, expected to cover about 450,000 people—roughly one in 10 residents. The project extends the company’s work in Singapore into broader clinical and public-health applications, offering a significant showcase for precision medicine. Article
• Neutral Sentiment: The large population covered by the study could create strategic opportunities, but no contract value, revenue timing, or sequencing volume for Illumina was disclosed, so the near-term financial impact is uncertain. Article
• Negative Sentiment: Citigroup raised its price target for ILMN but maintained a “sell” rating, indicating it still sees potential downside. Separately, commentary on the Q3 call cited persistent weakness in research and applied markets, despite strength in clinical sequencing and NovaSeq X placements. Article Article

Insider Buying and Selling at Illumina

In related news, Director Keith A. Meister sold 299,336 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the sale, the director owned 1,409,851 shares in the company, valued at $307,291,123.96. The trade was a 17.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,320,108 shares of company stock valued at $288,195,392 over the last quarter. Company insiders own 2.90% of the company’s stock.

Illumina Stock Performance

Illumina stock opened at $238.21 on Wednesday. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The stock has a market cap of $36.02 billion, a PE ratio of 41.00, a P/E/G ratio of 3.08 and a beta of 1.46. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35. The business’s 50-day moving average price is $249.74 and its two-hundred day moving average price is $177.05.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.26. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The firm’s revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.34 EPS. As a group, analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on ILMN shares. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Barclays raised their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a report on Wednesday, October 7th. Evercore restated an “underperform” rating on shares of Illumina in a research report on Friday. Finally, Leerink Partners upped their price target on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $244.24.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.